Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia

Journal of Infectious Diseases

Volumn 187, Issue 8, 2003, Pages 1223-1234

  Plested, Joyce S ^a,b   Harris, Shannon L ^d   Wright, J Claire ^a   Coull, Philip A ^a,b   Makepeace, Katherine ^a   Gidney, Margaret Anne J ^c   Brisson, Jean Robert ^c   Richards, James C ^c   Granoff, Dan M ^d   Moxon, E Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BLOOD CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; MENINGOCOCCOSIS; MOLECULAR MODEL; NEISSERIA MENINGITIDIS; NEWBORN; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SIALYLATION; WESTERN BLOTTING;

ANIMALS; ANIMALS, SUCKLING; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTEREMIA; BACTERIAL VACCINES; CONSERVED SEQUENCE; EPITOPES; IMMUNIZATION, PASSIVE; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MICE; MODELS, MOLECULAR; NEISSERIA MENINGITIDIS; PHYLOGENY; RATS; RATS, WISTAR;

EID: 0344837814     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368360     Document Type: Article

References (38)

1. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977; 136(Suppl):S31-5.
2. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001; 20:666-87.
3. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(Suppl 1):S58.67.
4. Granoff DM, Bartoloni A, Ricci S, et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998; 160:5028-36.
5. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183:97-104.
6. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-508.
7. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7.
8. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7.
9. Fusco PC, Michon F, Tai JY, Blake MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997; 175:364-72.
10. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MCJ, eds. Meningococcal vaccines. Totowa, NJ: Humana Press, 2001:81-107.
11. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-207.
12. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
13. Zollinger WD, Boslego J, Moran E, et al. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease. NIPH Ann 1991; 14:211-2.
14. De Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-8.
15. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 1995; 24:1050-7.
16. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664-75.
17. Verheul AFM, Snippe H, Poolman JT. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev 1993; 57:34-45.
18. Scholten RJ, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol 1994; 41:236-43.
19. Jennings MP, Srikhanta YN, Moxon ER, et al. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 1999; 145:3013-21.
20. Banerjee A, Wang R, Uljon SN, Rice PA, Gotschlich EC, Stein DC. Identification of the gene (lgtG) encoding the lipooligosaccharide beta chain synthesizing glucosyl transferase from Neisseria gonorrhoeae. PNAS 1998; 95:10872-7.
21. Plested JS, Makepeace K, Jennings MP, et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun 1999; 67:5417-26.
22. Plested JS, Ferry BL, Coull PA, et al. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry. Infect Immun 2001; 69:3203-13.
23. Plested JS, Gidney MA, Coull PA, et al. Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B. J Immunol Methods 2000; 237:73-84.
24. Perry MB, Bundle DR, Gidney MA, Lior H. Identification of Escherichia coli serotype O157 strains by using a monoclonal antibody. J Clin Microbiol 1988; 26:2391-4.
25. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 2001; 69:3762-71.
26. Zollinger WD, Moran EE, Devi SJ, Frasch CE. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun 1997; 65:1053-60.
27. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182:1169-76.
28. Caugant DA, Bovre P, Gaustad P, et al. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol 1986; 132:641-52.
29. Virji M, Kayhty H, Ferguson DJP, Heckels JE, Moxon ERM. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Mol Microbiol 1991; 5:1831-41.
30. Van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on class 1 outer membrane protein. Infect Immun 1992; 60:3156-61.
31. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. PNAS 1998; 95:3140-5.
32. Seiler A, Reinhardt R, Sakari A, Caugant DA, Achtman M. Allelic polymorphisms and site-specific recombination in the opc locus of Neisseria meningitidis. Mol Microbiol 1996; 19:841-56.
33. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 1979; 9:186-8.
34. Jennings MP, van der Ley P, Wilks KE, Maskell DJ, Poolman JT, Moxon ER. Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis. Mol Microbiol 1993; 10:361-9.
35. Mackinnon FG, Cox AD, Plested JS, et al. Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosis. Mol Microbiol 2002; 43:931-43.
36. Abdillahi H, Poolman JT. Typing of group B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J Med Microbiol 1988; 26:177-80.
37. Lesse AJ, Campagnari AA, Bittner WE, Apicella MA. Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricinesodium dodecyl sulfate-polyacrylamide gel electrophoresis. J Immunol Methods 1990; 126:109-17.
38. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 1992; 24:145-9.